Arganini M, Spinelli C, Cecchini G M, Miccoli P
Istituto di Clinica Chirurgica-Cattedra di Anatomia Chirurgica, Università degli Studi di Pisa, Italia.
Acta Chir Belg. 1989 Jul-Aug;89(4):209-11.
Carcinoid tumor associated with carcinoid syndrome is a very difficult condition to treat. Many different drugs have been used in order to control symptoms and different antineoplastic agents were experimentated to reduce the often large neoplastic lesions. Recently the description of the existence of estrogen receptors in carcinoid tumor tissue arose great enthusiasm on the possibility of using the antiestrogen tamoxifen as a direct antitumor agent. Few experiences appeared in the international literature and contrastant results were reported. In this paper we describe one case of long term treatment with tamoxifen for a metastatic carcinoid tumor. The patient experienced the regression of carcinoid syndrome symptoms with tamoxifen therapy. Unfortunately after one year symptoms reappeared in spite of tamoxifen therapy. We conclude that tamoxifen is at the moment the best therapy in patient affected by carcinoid tumor associated with carcinoid syndrome. Data on other drugs as the oral analogues of Somatostatin or Calcitonin need to be confirmed by additional studies.
类癌瘤伴类癌综合征是一种极难治疗的病症。为了控制症状，人们使用了许多不同的药物，并试验了不同的抗肿瘤药物以缩小通常较大的肿瘤病灶。最近，类癌瘤组织中雌激素受体的存在这一描述引发了人们对使用抗雌激素他莫昔芬作为直接抗肿瘤药物的可能性的极大热情。国际文献中出现的相关经验很少，且报道的结果相互矛盾。在本文中，我们描述了一例用他莫昔芬长期治疗转移性类癌瘤的病例。该患者在他莫昔芬治疗后类癌综合征症状出现缓解。不幸的是，尽管进行了他莫昔芬治疗，一年后症状再次出现。我们得出结论，目前他莫昔芬是治疗类癌瘤伴类癌综合征患者的最佳疗法。关于其他药物如生长抑素或降钙素的口服类似物的数据需要更多研究加以证实。
